"Hope, like the gleaming taper’s light, Adorns and cheers our way;
And still, as darker grows the night, Emits a brighter ray."
— Oliver Goldsmith (1730?–1774)

CML Medical Journal Articles

  • Home
  • Gleevec Resource Center
  • Back to CML Medical Journal Articles


      Journal Articles About CML

    LEUKEMIA

  • Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
    August 2004

  • Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
    August 2004

  • Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during treatment of Philadelphia-positive chronic myeloid leukemia
    August 2004

  • Visual disturbance due to retinal edema as a complication of imatinib
    June 2004

  • Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized, controlled trial
    December 2003

  • Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program
    December 2003

  • Prognostic factors for patients with chronic myeloid leukemia in chronic phase treated with imatinib mesylate after failure of interferon alpha
    Leukemia (2003) 17, 1448-1453

  • Dose-limiting dermatologic toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia
    Leukemia (2003) 17, 1414-1416

  • Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies
    Leukemia (2003) 17, 1211-1262

  • Questioning the aim of CML therapy in the age of imatinib
    Leukemia (2003) 17, 1199-1200

  • Detection of minimal residual disease in hematological malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
    Leukemia (2003) 17, 1013-1034

  • Current CML therapy: Progress and dilemma
    Leukemia (2003) 17, 1010-1012

  • Histological features of acute hepatitis after imatinib mesylate treatment
    Leukemia (2003) 17, 978-979

  • Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back
    Leukemia (2003)17, 829-838

  • Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR
    Leukemia (2003) 17, 821-828

  • Correspondence: G-CSF for imatinib-induced neutropenia
    Leukemia (2003) 17, 805-807

  • Intramuscular edema as a complication of treatment with imatinib
    Leukemia (2003) 17, 804-810

  • Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL
    Leukemia (2003) 17, 691-699

  • Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate
    Leukemia (2003) 17, 481-487

  • Spotlight on signal transduction inhibitors: Molecular targets for therapy, signal transduction inhibition and imatinib
    Leukemia (2002) 16, 1205-1206

  • Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective
    Leukemia (2002) 16, 1213–1219

  • Chronic myelogenous leukemia: mechanisms underlying disease progression
    Leukemia (2002) 16, 1402–1411

  • STI-571 must select for drug-resistant cells but "no cell breathes fire out of its nostrils like a dragon"
    Leukemia (2002) 16, 570–572

  • Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo
    Leukemia (2002) 16, 1484–1489

  • E19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts
    Leukemia (2002) 16, 1562–1578

  • Results Of A Phase II Trial Of A Combination Of Oral Cytarabine Ocfosfate (YNK01) And Interferon Alpha-2b For The Treatment Of Chronic Myelogenous Leukemia Patients In Chronic Phase
    Leukemia (2002) 16, 573–580

  • Nitric Oxide Induces The Apoptosis Of Human BCR-ABL-Positive Myeloid Leukemia Cells: Evidence For The Chelation Of Intracellular Iron
    Leukemia (2002) 16, 708–715

  • Elucidating Critical Mechanisms Of Deregulated Stem Cell Turnover In The Chronic Phase Of Chronic Myeloid Leukemia
    Leukemia (2002) 16, 549–558

  • Abnormality Of C-kit Oncoprotein In Certain Patients With Chronic Myelogenous Leukemia – Potential Clinical Significance
    Leukemia (2002) 16

  • Tyrosine Kinase Fusion Genes In Chronic Myeloproliferative Diseases
    Leukemia (2002) 16, 1207–1212

  • Detection And Quantification Of Residual Disease In Chronic Myelogenous Leukemia
    Leukemia (2000) 14, 998–1005

  • Effect Of Interferon-Alpha Therapy On Bone Marrow Fibrosis In Chronic Myelogenous Leukemia
    Leukemia (1998) 12, 65–70

  • GM-CSF Can Improve The Cytogenetic Response Obtained With Interferon-Alpha Therapy In Patients With Chronic Myelogenous Leukemia
    Leukemia (1998) 12, 860–864





    • Give me a holler





    Today Is:





    © 2000-2004 CMLSupport.com Inc. All rights reserved.

    These contents may not be reproduced in whole or in part in any medium without the express written permission of CMLSupport.com Inc. This site is best viewed with Internet Explorer.

    		•